FI962155L - Uudet 9-hydroksipyrido (1,2-a) pyrimidin-4-onieetterijohdannaiset - Google Patents

Uudet 9-hydroksipyrido (1,2-a) pyrimidin-4-onieetterijohdannaiset Download PDF

Info

Publication number
FI962155L
FI962155L FI962155A FI962155A FI962155L FI 962155 L FI962155 L FI 962155L FI 962155 A FI962155 A FI 962155A FI 962155 A FI962155 A FI 962155A FI 962155 L FI962155 L FI 962155L
Authority
FI
Finland
Prior art keywords
hydroxypyrido
pyrimidin
new
ether derivatives
derivatives
Prior art date
Application number
FI962155A
Other languages
English (en)
Swedish (sv)
Other versions
FI962155A0 (fi
FI112483B (fi
Inventor
Jan Vandenberk
Ludo Edmond Josephine Kennis
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of FI962155L publication Critical patent/FI962155L/fi
Publication of FI962155A0 publication Critical patent/FI962155A0/fi
Application granted granted Critical
Publication of FI112483B publication Critical patent/FI112483B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI962155A 1993-11-23 1996-05-22 Menetelmä terapeuttisesti käyttökelpoisten 3-[2-[4-(6-fluori-1,2-bentsisoksatsol-3-yyli) -1-piperidinyyli]etyyli]-2-alkyyli-pyrimidin-4-onijohdannaisten valmistamiseksi FI112483B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93203270 1993-11-23
PCT/EP1994/003804 WO1995014691A1 (en) 1993-11-23 1994-11-16 NOVEL 9-HYDROXY-PYRIDO[1,2-a]PYRIMIDIN-4-ONE ETHER DERIVATIVES

Publications (3)

Publication Number Publication Date
FI962155L true FI962155L (fi) 1996-05-22
FI962155A0 FI962155A0 (fi) 1996-05-22
FI112483B FI112483B (fi) 2003-12-15

Family

ID=8214180

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962155A FI112483B (fi) 1993-11-23 1996-05-22 Menetelmä terapeuttisesti käyttökelpoisten 3-[2-[4-(6-fluori-1,2-bentsisoksatsol-3-yyli) -1-piperidinyyli]etyyli]-2-alkyyli-pyrimidin-4-onijohdannaisten valmistamiseksi

Country Status (14)

Country Link
US (1) US5688799A (fi)
EP (1) EP0730594B1 (fi)
JP (1) JP3553951B2 (fi)
AT (1) ATE184281T1 (fi)
AU (1) AU687940B2 (fi)
CA (1) CA2175372C (fi)
DE (1) DE69420579T2 (fi)
DK (1) DK0730594T3 (fi)
ES (1) ES2137486T3 (fi)
FI (1) FI112483B (fi)
GR (1) GR3031500T3 (fi)
RU (1) RU2126406C1 (fi)
SI (1) SI0730594T1 (fi)
WO (1) WO1995014691A1 (fi)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2141671B1 (es) * 1997-12-26 2001-01-01 Vita Invest Sa Compuesto pirimidinico activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
WO2004009591A1 (en) * 2002-07-22 2004-01-29 Aurobindo Pharma Ltd. A process for the preparation of antipsychotic risperidone
AU2003256006A1 (en) * 2002-08-30 2004-03-19 Sunil Sadanand Nadkarni Improved process for preparation of risperidone
HUP0401379A3 (en) * 2004-07-08 2006-04-28 Richter Gedeon Vegyeszet Process for the preparation of risperidon
EP1791839B1 (en) * 2004-09-09 2015-06-10 Janssen Pharmaceutica NV Preparation of 9-hydroxy-3-(2-hydroxyethyl)-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one and crystalls thereof
HUP0402163A2 (en) * 2004-10-25 2006-05-29 Richter Gedeon Vegyeszet Process for the preparation of risperidone
US20080177067A1 (en) * 2006-08-14 2008-07-24 Ben-Zion Dolitzky Crystal forms of 9-hydroxy-risperidone (paliperidone)
DE202007018473U1 (de) 2006-08-14 2008-08-07 Teva Pharmaceutical Industries Ltd. 9-Hydroxy-Risperidon (Paliperidon)
US7820816B2 (en) 2006-08-23 2010-10-26 Teva Pharmaceutical Industries Ltd. Process for the synthesis of CMHTP and intermediates thereof
CN101600716A (zh) 2007-01-08 2009-12-09 阿特维斯集团公司 用于制备9-羟基-3-(2-氯乙基)-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮盐酸盐的改进方法
US20080171876A1 (en) * 2007-05-10 2008-07-17 Santiago Ini Pure paliperidone and processes for preparing thereof
WO2009010988A1 (en) * 2007-07-19 2009-01-22 Natco Pharma Limited An improved, industrially viable process for the preparation of high purity paliperidone
WO2009015828A1 (en) * 2007-07-27 2009-02-05 Synthon B.V. Paliperidone derivatives
US20090087487A1 (en) * 2007-08-21 2009-04-02 Michael Fox Paliperidone sustained release formulation
WO2009056990A2 (en) * 2007-08-21 2009-05-07 Actavis Group Ptc Ehf Paliperidone polymorphs
WO2009044413A2 (en) * 2007-10-05 2009-04-09 Matrix Laboratories Limited Improved process for preparing paliperidone, novel polymorphic forms of the same and process thereof
WO2009070306A1 (en) * 2007-11-27 2009-06-04 Teva Pharmaceutical Industries Ltd. Processes for preparing crystal forms of 9-hydroxy-risperidone (paliperidone)
CL2008003667A1 (es) * 2007-12-10 2010-06-04 Synthon Bv Proceso de preparacion de etil-6,7,8,9-tetrahidro-9-hidroxi-2-metil-4h-pirido[1,2-a]piridin-4-ona; y uno de los intermediarios considerados en el proceso descrito; util en la preparacion de paliperidona.
TWI385157B (zh) * 2008-01-16 2013-02-11 Scinopharm Taiwan Ltd 用於製備帕潘立酮（ｐａｌｉｐｅｒｉｄｏｎｅ）之新穎中間體
WO2009116071A2 (en) * 2008-02-05 2009-09-24 Watson Pharma Private Limited An improved process for preparation of paliperidone
US20090247553A1 (en) * 2008-03-27 2009-10-01 Actavis Group Ptc Ehf Highly Pure Paliperidone or a Pharmaceutically Acceptable Salt Thereof Substantially Free of Keto Impurity
EP2303877B1 (en) 2008-05-29 2017-02-15 Inke, S.A. Process to prepare paliperidone and intermediates thereof
EP2300467A4 (en) 2008-06-16 2012-04-25 Msn Lab Ltd NEW AND IMPROVED METHODS FOR THE MANUFACTURE OF PALIPERIDONE
US20100010218A1 (en) * 2008-07-11 2010-01-14 Jiri Bartl Synthesis of paliperidone
EP2318405A2 (en) 2008-07-11 2011-05-11 Synthon B.V. Paliperidone ketone
WO2010064134A2 (en) * 2008-12-05 2010-06-10 Cadila Pharmaceuticals Ltd. Process of synthesis of paliperidone
EP2202234A1 (en) 2008-12-24 2010-06-30 Laboratorios Lesvi, S.L. Purification of paliperidone
US20120100188A1 (en) 2009-05-28 2012-04-26 Actavis Group Ptc Ehf Solid state forms of paliperidone salts and process for the preparation thereof
EP2475663A2 (en) 2009-09-10 2012-07-18 Actavis Group Ptc Ehf Paliperidone or a pharmaceutically acceptable salt thereof substantially free of impurities
WO2011073997A2 (en) * 2009-12-14 2011-06-23 Cadila Healthcare Limited Process for preparing paliperidone and pharmaceutically acceptable salts thereof
US8088594B2 (en) * 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
WO2012035554A1 (en) 2010-09-14 2012-03-22 Megafine Pharma (P) Ltd. An improved process for the preparation of highly pure paliperidone
CN103387575A (zh) * 2013-07-22 2013-11-13 江苏万特制药有限公司 帕潘立酮的制备方法及其关键中间体
KR101867988B1 (ko) * 2016-11-02 2018-06-15 주식회사 엔지켐생명과학 팔리페리돈 중간체 및 이를 이용한 팔리페리돈의 제조방법
CN115260190A (zh) * 2022-08-30 2022-11-01 南开大学 一种帕利哌酮前药、制剂及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485107A (en) * 1982-11-01 1984-11-27 Janssen Pharmaceutica N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
CA2000786C (en) * 1988-11-07 1999-01-26 Janssen Pharmaceutica, Naamloze Vennootschap 3-piperidinyl-1,2-benzisoxazoles
GB9008850D0 (en) * 1990-04-19 1990-06-13 Janssen Pharmaceutica Nv Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones

Also Published As

Publication number Publication date
RU2126406C1 (ru) 1999-02-20
AU687940B2 (en) 1998-03-05
CA2175372C (en) 2006-02-21
ATE184281T1 (de) 1999-09-15
CA2175372A1 (en) 1995-06-01
EP0730594B1 (en) 1999-09-08
SI0730594T1 (en) 1999-12-31
GR3031500T3 (en) 2000-01-31
DK0730594T3 (da) 2000-03-27
JP3553951B2 (ja) 2004-08-11
FI962155A0 (fi) 1996-05-22
US5688799A (en) 1997-11-18
WO1995014691A1 (en) 1995-06-01
JPH09505574A (ja) 1997-06-03
FI112483B (fi) 2003-12-15
DE69420579T2 (de) 2000-04-27
ES2137486T3 (es) 1999-12-16
EP0730594A1 (en) 1996-09-11
DE69420579D1 (de) 1999-10-14
AU1065495A (en) 1995-06-13

Similar Documents

Publication Publication Date Title
MX9202838A (es) Imidazo[1,5-a]quinoxalinas.
NO974595D0 (no) Imidazo£1,2-a|pyridin-derivater
DK0447891T3 (da) Thieno(2,3-d)pyrimidinderivater
FI933248L (fi) Optiskt aktiva 5h-pyrrolo(3,4-b)pyrazinderat, dess framstaellning och farmaceutiska kompositioner innehaollande detta
DK0680488T3 (da) 2,6-Diaminopurinderivater
FI954088A7 (fi) Pyrrolopyridiinijohdannaisia
ATE214704T1 (de) 5h-thiazolo(3,2-a)pyrimidinderivate
DE69529777D1 (de) 2-Benzylthio-8-amino(1,2,4)triazolo(1,5-a)pyridine
DE69114654D1 (de) Fluorierte Diazabicycloalkan-Derivate.
FI961564L (fi) Imidatso(1,2-a)pyridiinien alkoksialkyylikarbamaatit
FI934182L (fi) Foerfarande foer framstaellning av 5-substituerade pyrrolo(2,3-d)pyrimidiner
DE69615404D1 (de) 2,7-SUBSTITUIERTE OCTAHYDROPYRROLO(1,2-a)PYRAZINDERIVATE
BR9701675A (pt) Novos pirimido(1,2-a)indóis
FI971310L (fi) 2,7-substituoituja oktahydro-1H-pyrido/1,2-a/pyratsiinijohdannaisia
FI923290A7 (fi) Imidatso(2,1-b)bentsotiatsoli-3-asetamidijohdannaisia
FI20000354L (fi) Perhydro-1H-pyrido/1,2-a/pyratsiinijohdannaiset
DK232387D0 (da) Diastereoisomere tetrahydropyrido (2,3-d) pyrimi- din derivativer
FI864891A7 (fi) Foerfarande foer framstaellning av 6,7,8,9-tetrahydro-10-metylpyrido/1,2-a/indol-9-aminer och deras derivat.
NO895217L (no) Substituerte pyrido(2,3-d)pyrimidiner.
FI906270A0 (fi) Imidazo/4,5-c/pyridiner som antiosteoporotiska aemnen.
FI943999A7 (fi) Pyrido(1,2,3-d,e)(1,3,4)bentsoksadiatsiinijohdannaisia
DE3682244D1 (de) Substituierte dihydroimidazo(1,2-a)chinoxalinderivate.
DE69425117D1 (de) Fluorierte Diazabicycloalkanderivate
FI940607A7 (fi) Imidatso(5,1-C)(1,4)bentsoksatsin-1-onijohdannaiset 5HT3-antagonisteina
ATE115144T1 (de) Antivirale tetrahydroimidazo(1,4>benzodiazepine.